

What is claimed is:

- 1 1. An enveloped pharmaceutical composition comprising:
2 a first active available for immediate release; and
3 a second active for extended release selected from the group consisting of a
4 decongestant, an antihistamine, an expectorant, an antitussive and mixtures thereof,
5 wherein the first and the second active are disposed on separate carriers.
- 1 2. The composition of claim 1, wherein the first and second actives are enveloped in
2 a single dose.
- 1 3. The composition of claim 1, wherein the first and second actives are enveloped
2 into a single dose.
- 1 4. The composition of claim 1, wherein the first and second actives are packed into a
2 capsule, caplet, softgel, gelcap, suppository, film, granule, gum, insert, pastille, pellet,
3 troche, lozenge, disk, poultice or wafer.
- 1 5. The composition of claim 1, wherein over 80% of the first active is released
2 within about 60 minutes.
- 1 6. The composition of claim 1, wherein immediate release is defined further as
2 comprising release of over 90% of the first active within about 90 minutes.
- 1 7. The composition of claim 1, wherein extended release is defined further as
2 comprising release of over 80% of the second active within about 60 minutes to about 8
3 hours.
- 1 8. The composition of claim 1, wherein extended release is defined further as
2 comprising release of over 90% of the second active within about 90 minutes to about 6
3 hours.
- 1 9. The composition of claim 1, wherein the first active comprises gauifenesin.
- 1 10. The composition of claim 1, wherein the first active comprises gauifenesin DC in
2 a powder form.

- 1 11. The composition of claim 1, wherein the first active comprises 211 mg of 95%
2 gauifenesin.
- 1 12. The composition of claim 1, wherein the second active comprises a nasal
2 decongestant.
- 1 13. The composition of claim 1, wherein the second active comprises phenylephrine.
- 1 14. The composition of claim 1, wherein the second active comprises phenylephrine
2 as a sustained release bead.
- 1 15. The composition of claim 1, wherein the second active comprises phenylephrine
2 as a layered sustained release bead.
- 1 16. The composition of claim 1, wherein the second active comprises three or more
2 layers of phenylephrine on a bead.
- 1 17. The composition of claim 1, wherein the first active is superposed on the second
2 active.
- 1 18. The composition of claim 1, comprising further one or more inactives.
- 1 19. The composition of claim 1, wherein the first active for immediate release
2 comprises a powder form and the second active comprises a beaded form.
- 1 20. An enveloped pharmaceutical composition comprising:
2 a first active available for immediate release; and
3 a second active available for extended release, wherein the first active effects a
4 physiological result that improves the physiological action of the second active upon
5 extended release.
- 1 21. The composition of claim 20, wherein the first and second actives are enveloped
2 in a single dose.
- 1 22. The composition of claim 20, wherein the first and second actives are enveloped
2 into a single dose.

- 1 23. The composition of claim 20, wherein the first and second actives are packed into
2 a capsule, caplet, softgel, gelcap, suppository, film, granule, gum, insert, pastille, pellet,
3 troche, lozenge, disk, poultice or wafer.
- 1 24. The composition of claim 20, wherein over 80% of the first active is released
2 within about 60 minutes.
- 1 25. The composition of claim 20, wherein immediate release is defined further as
2 comprising release of over 90% of the first active within about 90 minutes.
- 1 26. The composition of claim 20, wherein extended release is defined further as
2 comprising release of over 80% of the second active within about 60 minutes to about 8
3 hours.
- 1 27. The composition of claim 20, wherein extended release is defined further as
2 comprising release of over 90% of the second active within about 90 minutes to about 6
3 hours.
- 1 28. The composition of claim 20, wherein the second active for extended release is
2 selected from the group consisting of a decongestant, an antihistamine, an expectorant, an
3 antitussive and mixtures thereof.
- 1 29. The composition of claim 20, wherein the first active comprises gauifenesin.
- 1 30. The composition of claim 20, wherein the first active comprises Gauifenesin DC
2 in a powder form.
- 1 31. The composition of claim 20, wherein the first active comprises 211 mg of 95%
2 gauifenesin.
- 1 32. The composition of claim 20, wherein the second active comprises a nasal
2 decongestant.
- 1 33. The composition of claim 20, wherein the second active comprises phenylephrine.
- 1 34. The composition of claim 20, wherein the second active comprises phenylephrine
2 as a sustained release bead.

1 35. The composition of claim 20, wherein the second active comprises phenylephrine
2 as a layered sustained release bead.

1 36. The composition of claim 20, wherein the second active comprises three or more
2 layers of phenylephrine on a bead.

1 37. The composition of claim 20, wherein the first active is superposed on the second
2 active.

1 38. The composition of claim 20, comprising further one or more inactives.

1 39. The composition of claim 20, wherein the first active for immediate release
2 comprises a powder form and the second active comprises a beaded form.

1 40. An enveloped pharmaceutical composition comprising:
2 a first active packaged so that over 90 % of the first active is released within about
3 90 minutes; and
4 a second active for extended release selected from the group consisting of a decongestant,
5 an antihistamine, an expectorant, an antitussive and mixtures thereof, wherein over 90%
6 of the second active is released between about 1 and 6 hours.

1 41. The composition of claim 40, wherein the first and the second actives are
2 disposed on separate carriers.

1 42. The composition of claim 40, wherein the first and second actives are enveloped
2 in a single dose.

1 43. The composition of claim 40, wherein the first and second actives are enveloped
2 into a single dose.

1 44. The composition of claim 40, wherein the first and second actives are packed into
2 a capsule, caplet, softgel, gelcap, suppository, film, granule, gum, insert, pastille, pellet,
3 troche, lozenge, disk, poultice or wafer.

1 45. The composition of claim 40, wherein over 80% of the first active is released
2 within about 60 minutes.

- 1 46. The composition of claim 40, wherein immediate release is defined further as
2 comprising release of over 90% of the first active within about 60 minutes.
- 1 47. The composition of claim 40, wherein extended release is defined further as
2 comprising release of over 80% of the second active within about 60 minutes to about 8
3 hours.
- 1 48. The composition of claim 40, wherein extended release is defined further as
2 comprising release of over 90% of the second active within about 90 minutes to about 6
3 hours.
- 1 49. The composition of claim 40, wherein the first active comprises gauifenesin.
- 1 50. The composition of claim 40, wherein the first active comprises gauifenesin in a
2 powder form.
- 1 51. The composition of claim 40, wherein the first active comprises 211 mg of 95%
2 gauifenesin.
- 1 52. The composition of claim 40, wherein the second active comprises a nasal
2 decongestant.
- 1 53. The composition of claim 40, wherein the second active comprises phenylephrine.
- 1 54. The composition of claim 40, wherein the second active comprises phenylephrine
2 as a sustained release bead.
- 1 55. The composition of claim 40, wherein the second active comprises phenylephrine
2 as a layered sustained release bead.
- 1 56. The composition of claim 40, wherein the second active comprises three or more
2 layers of phenylephrine on a bead.
- 1 57. The composition of claim 40, wherein the first active is superposed on the second
2 active.
- 1 58. The composition of claim 40, comprising further one or more inactives.

- 1 59. The composition of claim 40, wherein the first active for immediate release
2 comprises a powder form and the second active comprises a beaded form.
- 1 60. An enveloped pharmaceutical composition comprising:
2 a first active available for immediate effervescent release; and
3 a second active for extended release in a mini-tab selected from the group
4 consisting of a decongestant, an antihistamine, an expectorant, an antitussive and
5 mixtures thereof.
- 1 61. An enveloped pharmaceutical composition comprising:
2 a first active available for immediate release; and
3 a second active for extended release selected from the group consisting of a
4 decongestant, an antihistamine, an expectorant, an antitussive and mixtures thereof
5 wherein the first and second actives are different.
- 1 62. An liquid pharmaceutical composition comprising:
2 a first active available for immediate release; and
3 a second active coated on or about one or more suspended beads for extended
4 release selected from the group consisting of a decongestant, an antihistamine, an
5 expectorant, an antitussive and mixtures thereof, wherein the first active effects a
6 physiological result that improves the physiological action of the second active upon
7 extended release.
- 1 63. The liquid pharmaceutical composition of claim 62, wherein the first and second
2 active are made available in a solution, suspension, cream, ointment, lotion, enema,
3 elixir, syrup, emulsion, gum, insert, jelly, foam, paste, pastille, spray, magma or poultice.
- 1 62. A method of loading one or more actives on a bead for extended release
2 comprising:
3 adding a first active onto one or more beads with an adhesive and a sustained
4 release coating; and
5 adding a extended release coating prior to or in combination with a second active.

- 1 63. The method of claim 62, wherein the adhesive comprises a pharmaceutical glaze.
- 1 64. The method of claim 62, wherein the adhesive is a sustained release coating that
2 is added prior to the addition of the first active.
- 1 65. The method of claim 62, wherein the adhesive is a sustained release coating that
2 is added concurrent with the addition of the first active.
- 1 66. The method of claim 62, wherein the adhesive is a sustained release coating is
2 about or after the addition of the first active.
- 1 67. The method of claim 62, wherein the adhesive is a sustained release coating is
2 mixed with the first active, and the mixture is added onto one or more beads.
- 1 68. The method of claim 67, wherein the bead comprises a portion of a mini-tab.
- 1 69. The method of claim 62, further comprising the step of adding an erosion matrix.
- 1 70. The method of claim 62, further comprising the step of adding one or more
2 inactives.
- 1 71. A method of loading an active into a mini-tab to be encapsulated for extended
2 release, using an erosion matrix.
- 1 72. A method of providing a dual-release formulation comprising:
2 a first active in a powdered form and a second active in an extended release form,
3 wherein the first and second actives are loaded into a capsule.
- 1 73. A method of loading an active on a bead comprising:
2 adding the active onto one or more beads with a pharmaceutical glaze;
3 curing the active and the glaze for between about 3 to 6 hours prior to adding a
4 sustained release coating; and
5 repeating the steps of adding active and curing the active at least two more times.
- 1 74. The method of claim 73, wherein the active comprises a decongestant.
- 1 75. The method of claim 73, wherein the active comprises phenylephrine.

- 1 76. A method of providing a dual-release formulation comprising:
2 providing a first active comprising an expectorant packed for immediate release in
3 a powder form;
4 providing a second active comprising a nasal decongestant packed for extended
5 release on a bead, and
6 enveloping the first and the second actives, wherein the first active provides
7 productive coughs in the short-term and the second active provides long acting
8 decongestant activity.
- 1 77. A method of providing a dual-release formulation comprising:
2 providing a first active comprising an expectorant packed for immediate release in
3 a powder form;
4 providing a second active comprising a nasal decongestant packed for extended
5 release on a bead, and
6 encapsulating the first and the second actives, wherein the first active provides
7 productive coughs in the short-term and the second active provides long acting
8 decongestant activity.
- 1 78. A method of providing a dual-release formulation comprising:
2 providing a first active comprising an expectorant packed for immediate release in
3 a powder form;
4 providing a second active comprising a nasal decongestant packed for extended
5 release on a bead, and
6 suspending the first and the second actives in a liquid medium, wherein the first
7 active provides productive coughs in the short-term and the second active provides long
8 acting decongestant activity.